Pronetalol

Summary

Pronetalol (CHEMBL16476) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 229.32 Da · C15H19NO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL16476
Name	Pronetalol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4930
Molecular formula	C15H19NO
Molecular weight	229.32
InChIKey	HRSANNODOVBCST-UHFFFAOYSA-N

SMILES: CC(C)NCC(C1=CC2=CC=CC=C2C=C1)O

IUPAC name: 1-naphthalen-2-yl-2-(propan-2-ylamino)ethanol

Also known as: AY 6204 FREE BASE, AY-6204 FREE BASE, AY-6204 HCL, COMPOUND 38174, Dl-pronethalol, GNF-PF-2670, ICI 38174 FREE BASE, ICI-38174 FREE BASE, Inetol, Naphthylisoproterenol, Pronetalol, Pronethalol

Parent form; salt/anhydrous children: CHEMBL1876082

Patent coverage: 588 distinct patent families (2,670 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,667 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Beta-2 adrenergic receptor.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q28044	6.8	Kd	160	nM	CHEMBL_ACT_489307

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).